Theralase(R) Release’s 1Q2024 Financial Statements
TORONTO, ON / ACCESSWIRE / May 30, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ")...
Disability
AIDPH Provides Written Testimony on Senate Committee Dental Crisis Hearing
Testimony Offers Policy Solutions for Veterans, People with Disabilities, LGBTQIA+ People, and Rural CommunitiesWASHINGTON, DC / ACCESSWIRE / May 29,...
Assured Allies Announces a Multi-Year Partnership to Support CalPERS Long-Term Care Policyholders in Maintaining Their Independence
Assured Allies will provide the AgeAssured program to over 45,000 CalPERS policyholders for a period of at least 5 yearsAgeAssured...
IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757
GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics...
Veru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Study in the Journal of the American Heart Association Links Hello Heart Usage to Significant Reductions in Blood Pressure, Cholesterol, and Weight
MENLO PARK, Calif.--(BUSINESS WIRE)--A new peer-reviewed study in the Journal of the American Heart Association found that Hello Heart’s digital...
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X SyndromeSAN...
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Patients for Patient Safety US Receives $100,000 to Launch ‘Project PIVOT,’ a Novel, Patient-Centered Initiative to Improve Healthcare
WASHINGTON, D.C. / ACCESSWIRE / May 13, 2024 / The Patient-Centered Outcomes Research Institute (PCORI) awarded Patients for Patient Safety...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and...
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals...
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics...
Discovery World on Market Partners for Blue Star Museum Program
PARKERSBURG, WV / ACCESSWIRE / May 3, 2024 / Discovery World on Market is teaming up with Fight4Vets and Jan...
Veru to Present at the GLP-1 Based Therapeutics Summit
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low...
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline...
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage...
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director
George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines,...
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on...
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...